Sharma et al. reported that anti-CTLA-4 Abs (Ipilimumab and Tremelimumab) did not deplete Foxp3+ cells within the tumor microenvironment, but suggested modifying the Fc region of the antibodies to enhance Fc-mediated depletion of intratumoral Tregs (34). The gene discussed is CTLA4; the disease is neoplasm.